Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02120807
First received: April 21, 2014
Last updated: September 12, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)